Does L12.8 require prior authorization?

No, L12.8 does not require prior authorization (high confidence). Code is covered without prior authorization.

`L12.8` — Other pemphigoid

ICD-10-CM

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Medical records must document failure of conventional therapy, contraindication to conventional therapy, or presence of rapidly progressive disease to justify IVIg use.
When IVIg is used as a short-term adjunct while awaiting effect of conventional therapy, documentation must show concurrent conventional treatment and rationale for temporary IVIg use.
Documentation should demonstrate the presence of at least one qualifying indication (e.g., records documenting failure of conventional therapy, documentation of contraindication, or evidence of rapidly progressive disease and rationale for short-term IVIg use with conventional therapy).
Be aware that local contractors may require additional local documentation or definitions (e.g., local coverage determination/criteria), and providers should follow Noridian or applicable LCD requirements.

Patient has failed conventional therapy.
Conventional therapy is contraindicated for the patient.
Patient has rapidly progressive disease in which a clinical response could not be achieved quickly enough with conventional agents; IVIg may be given along with conventional treatments and used only until conventional therapy takes effect.
IVIg is covered when the patient has failed conventional therapy for the treated condition.
IVIg is covered when conventional therapy is contraindicated for the patient.
IVIg is covered for rapidly progressive disease when a clinical response cannot be achieved quickly enough using conventional agents and IVIg is used only short-term alongside conventional treatment until that therapy takes effect.

A55639 — Billing and Coding: Chemotherapy Agents for Non-Oncologic Conditions

J05

L34771 — Immune Globulins

J05

L37205 — Chemotherapy Drugs and their Adjuncts

J05

A57554 — Billing and Coding: Immune Globulins

J05

L39297 — Off-label Use of Rituximab and Rituximab Biosimilars

Ask Verity about documentation requirements, denial risks, or coverage in your state.